Top

Published in:

Open Access 01-12-2018 | Research article

Effects of topical vs injection treatment of cervical myofascial trigger points on headache symptoms in migraine patients: a retrospective analysis

Authors: Giannapia Affaitati, Raffaele Costantini, Claudio Tana, Domenico Lapenna, Cosima Schiavone, Francesco Cipollone, Maria Adele Giamberardino

Published in: The Journal of Headache and Pain | Issue 1/2018

Abstract

Background

In migraine patients with cervical myofascial trigger points whose target areas coincide with migraine sites (M + cTrPs), TrP anesthetic injection reduces migraine symptoms, but the procedure often causes discomfort. This study evaluated if a topical TrP treatment with 3% nimesulide gel has similar efficacy as the injection but produces lesser discomfort with higher acceptability by the patients.

Methods

Retrospective analysis of medical charts of M + cTrPs patients in the period January 2012–December 2016 at a single Headache Center. Three groups of 25 patients each were included, all receiving migraine prophylaxis (flunarizine 5 mg/day) for 3 months and symptomatic treatment on demand. Group 1 received no TrP treatment, group 2 received TrP injections (bupivacaine 5 mg/ml at basis, 3rd, 10th, 30th and 60th day), group 3 received daily TrP topical treatment with 1.5 g of 3% nimesulide gel for 15 consecutive days, 15 days interruption and again 15 consecutive days. The following were evaluated: monthly number of migraine attacks and rescue medications, migraine intensity; pain thresholds to skin electrical stimulation (EPTs) and muscle pressure stimulation (PPTs) in TrP and target (basis, 30th, 60th and 180th days); discomfort from, acceptability of and willingness to repeat treatment (end of study). ANOVA for repeated measures and 1-way ANOVA were used to assess temporal trends in each group and comparisons among groups, respectively. Significance level was set at p < 0.05.

Results

Migraine improved over time in all groups, but significantly more and earlier in those receiving TrP treatment vs no TrP treatment (0.02 < p < 0.0001, 30–180 days for intensity and rescue medication, 60–180 days for number). All thresholds in the non-TrP-treated group did not change over time, while significantly improving in both the injection and nimesulide gel groups (0.01 < p < 0.0001, 30–180 days). Improvement of migraine and thresholds did not differ in the two TrP-treated groups. Discomfort was significantly lower, acceptability and willingness to repeat treatment significantly higher (0.05 < p < 0.0001) with gel than injection.

Conclusion

In migraine patients, topical treatment of cervical TrPs with 5% nimesulide gel proves equally effective as TrP injection with local anesthetics but more acceptable by the patients. This treatment could be effectively associated to standard migraine prophylaxis to improve therapeutic outcomes.

Disease GBD, Injury I, Prevalence C (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet 390:1211–1259CrossRef

Headache Classification of the International Headache Society (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:627–808CrossRef

Martelletti P (2018) Migraine disability complicated by medication overuse. Eur J Neurol 25(10):1193–1194CrossRef

Costantini R, Affaitati G, Massimini F, Tana C, Innocenti P, Giamberardino MA (2016) Laparoscopic Cholecystectomy for Gallbladder Calculosis in Fibromyalgia Patients: Impact on Musculoskeletal Pain, Somatic Hyperalgesia and Central Sensitization. PLoS One 11(4):e0153408CrossRef

Costantini R, Affaitati G, Wesselmann U, Czakanski P, Giamberardino MA (2017) Visceral pain as a triggering factor for fibromyalgia symptoms in comorbid patients. Pain 158(10):1925–1937CrossRef

Costantini R, Di Bartolomeo N, Francomano F, Angelucci D, Innocenti P (2005) Epithelioid angiosarcoma of the gallbladder: case report. J Gastrointest Surg 9(6):822–825CrossRef

Giamberardino MA, Affaitati G, Costantini R (2006) Chapter 24 referred pain from internal organs. Handb Clin Neurol 81:343–361CrossRef

Giamberardino MA, Affaitati G, Fabrizio A, Costantini R (2011) Effects of treatment of myofascial trigger points on the pain of fibromyalgia. Curr Pain Headache Rep 15(5):393–399CrossRef

Giamberardino MA, Affaitati G, Fabrizio A, Costantini R (2011) Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol 25(2):185–198CrossRef

10.

Giamberardino MA, Affaitati G, Martelletti P, Tana C, Negro A, Lapenna D et al (2015) Impact of migraine on fibromyalgia symptoms. J Headache Pain. 17:28CrossRef

11.

Giamberardino MA, Tafuri E, Savini A, Fabrizio A, Affaitati G, Lerza R et al (2007) Contribution of myofascial trigger points to migraine symptoms. J Pain 8(11):869–878CrossRef

12.

Giamberardino MA, Tana C, Costantini R (2014) Pain thresholds in women with chronic pelvic pain. Curr Opin Obstet Gynecol 26(4):253–259CrossRef

13.

Giamberardino MA, Vecchiet L (1995) Visceral pain, referred hyperalgesia and outcome: new concepts. Eur J Anaesthesiol (Suppl) 10:61–66

14.

Tana C, Tafuri E, Tana M, Martelletti P, Negro A, Affaitati G et al (2013) New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain 14:9CrossRef

15.

Costantini R, Sardellone A, Marino C, Giamberardino MA, Innocenti P, Napolitano AM (2005) Vacuum-assisted core biopsy (Mammotome) for the diagnosis of non-palpable breast lesions: four-year experience in an Italian center. Tumori 91(4):351–354PubMed

16.

Ko EJ, Jeon JY, Kim W, Hong JY, Yi YG (2017) Referred symptom from myofascial pain syndrome: One of the most important causes of sensory disturbance in breast cancer patients using taxanes. Eur J Cancer Care (Engl) 26:6CrossRef

17.

Gerwin RD (2016) Myofascial trigger point pain syndromes. Semin Neurol 36(5):469–473CrossRef

18.

Calandre EP, Hidalgo J, García-Leiva JM, Rico-Villademoros F (2006) Trigger point evaluation in migraine patients: an indication of peripheral sensitization linked to migraine predisposition? Eur J Neurol 13(3):244–249CrossRef

19.

Cummings M, Baldry P (2007) Regional myofascial pain: diagnosis and management. Best Prac Res Clin Rheumatol 21:367–387CrossRef

20.

Do TP, Heldarskard GF, Kolding LT, Hvedstrup J, Schytz HW (2018) Myofascial trigger points in migraine and tension-type headache. J Headache Pain 19(1):84CrossRef

21.

Fernández-de-Las-Peñas C (2015) Myofascial head pain. Curr Pain Headache Rep 19(7):28CrossRef

22.

Fernández-de-Las-Peñas C, Cuadrado ML, Pareja JA (2006) Myofascial trigger points, neck mobility and forward head posture in unilateral migraine. Cephalalgia 26:1061–1070CrossRef

23.

Tali D, Menahem I, Vered E, Kalichman L (2014) Upper cervical mobility, posture and myofascial trigger points in subjects with episodic migraine: case-control study. J Bodyw Mov Ther 18:569–575CrossRef

24.

Vecchiet L, Giamberardino MA, Saggini R (1991) Myofascial pain syndromes: clinical and patophysiological aspects. Clin J Pain 7:16–22CrossRef

25.

Affaitati G, Giamberardino MA, Lapenna D, Costantini R (2018) Diclofenac epolamine topical patch for the treatment of pain. J Biol Regul Homeost Agents 32(3):435–441PubMed

26.

Affaitati G, Fabrizio A, Savini A, Lerza R, Tafuri E, Costantini R et al (2009) A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Clin Ther 31(4):705–720CrossRef

27.

Buchgreitz L, Lyngberg AC, Bendtsen L, Jensen R (2008) Increased pain sensitivity is not a risk factor but a consequence of frequent headache: a population-based follow-up study. Pain 137(3):623–630CrossRef

28.

Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH (2000) An association between migraine and cutaneous allodynia. Ann Neurol 47:614–624CrossRef

29.

Kitaj MB, Klink M (2005) Pain thresholds in daily transformed migraine versus episodic migraine headache patients. Headache 45:992–998CrossRef

30.

Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML et al (2008) Cutaneous allodynia in the migraine population. Ann Neurol 63:148–158CrossRef

31.

Vecchiet L, Giamberardino MA, Dragani L, De Bigontina P, Albe-Fessard D (1990) Latent myofascial trigger points: changes in muscular and in subcutaneous pain thresholds at trigger point and target level. J Man Med 5:151–154

32.

Simons DG (2008) New views of myofascial trigger points: etiology and diagnosis. Arch Phys Med Rehabil 89:157–159CrossRef

33.

Simons DG, Mense S (2003) Diagnosis and therapy of myofascial trigger points. Schmerz 17:419–424CrossRef

34.

Simons DG, Travell JG, Simons LS (1999) Travell & Simons’ myofascial pain and dysfunction. In: The trigger point manual. Vol 1, upper half of body, 2nd edn. Williams & Wilkins, Baltimore

35.

Affaitati G, Fabrizio A, Frangione V, Lanzarotti A, Lopopolo M, Tafuri E et al (2015) Effects of topical diclofenac plus heparin (DHEP+H plaster) on somatic pain sensitivity in healthy subjects with a latent algogenic condition of the lower limb. Pain Pract 15(1):58–67CrossRef

36.

Al-Abd AM, Al-Abbasi FA, Nofal SM, Khalifa AE, Williams RO, El-Eraky WI et al (2014) Nimesulide improves the symptomatic and disease modifying effects of leflunomide in collagen induced arthritis. PLoS One 9(11):e111843CrossRef

37.

Kress HG, Baltov A, Basiński A, Berghea F, Castellsague J, Codreanu C et al (2016) Acute pain: a multifaceted challenge - the role of nimesulide. Curr Med Res Opin 32(1):23–36CrossRef

38.

Rainsford KD (2006) Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology 14(3–4):120–137CrossRef

39.

Rainsford KD (2006) Nimesulide a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 22(6):1161–1170CrossRef

40.

Ergün H, Külcü D, Kutlay S, Bodur H, Tulunay FC (2007) Efficacy and safety of topical nimesulide in the treatment of knee osteoarthritis. Clin Rheumatol 13(5):251–255CrossRef

41.

Gupta SK, Ptrakash J, Awor L, Velpandian T, Sengupta S (1996) Anti-inflammatory activity of topical nimesulide gel in various experimental models. Inflamm Res 45(12):590–592CrossRef

42.

Shah JP, Phillips TM, Danoff JV, Gerber LH (2005) An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol 99:1977–1984CrossRef

43.

Headache Classification of the International Headache Society (2004) The International Classification of headache disorders, Cephalalgia, vol 24(1), 2nd edn, pp 1–151

44.

Obrosova IG (2009) Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics 6:638–647CrossRef

45.

Viggiano A, Zagaria N, Passavanti MB, Pace MC, Paladini A, Aurilio C et al (2009) New and low-cost auto-algometry for screening hypertension-associated hypoalgesia. Pain Pract 9:260–265CrossRef

46.

Affaitati G, Martelletti P, Lopopolo M, Tana C, Massimini F, Cipollone F et al (2017) Use of nonsteroidal anti-inflammatory drugs for symptomatic treatment of episodic headache. Pain Pract 17(3):392–401CrossRef

47.

Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B et al (2011) A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain 12(3):361–368CrossRef

48.

Karsan N, Palethorpe D, Rattanawong W, Marin JC, Bhola R, Goadsby PJ (2018) Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK. Eur J Neurol 25(6):811–817CrossRef

49.

Loder E, Rizzoli P (2018) Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache. https://doi.org/10.1111/head.13375 [Epub ahead of print]CrossRef

50.

Pomes LM, Gentile G, Simmaco M, Borro M, Martelletti (2018) Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine. CNS Drugs. https://doi.org/10.1007/s40263-018-0532-6 [Epub ahead of print]CrossRef

51.

Giamberardino MA, Affaitati G, Costantini R, Cipollone F, Martelletti P (2017) Calcitonin gene-related peptide receptor as a novel target for the management of people with eptisodic migraine: current evidence and safety profile of erenumab. J Pain Res 10:2751–2760CrossRef

52.

Giamberardino MA, Affaitati G, Curto M, Negro A, Costantini R, Martelletti P (2016) Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med 11(8):1045–1057CrossRef

53.

Giamberardino MA, Costantini R, Affaitati G, Fabrizio A, Lapenna D, Tafuri E et al (2010) Viscero-visceral hyperalgesia: characterization in different clinical models. Pain 151(2):307–322CrossRef

54.

Giamberardino MA, Affaitati G, Lerza R, Lapenna D, Costantini R, Vecchiet L (2005) Relationship between pain symptoms and referred sensory and trophic changes in patients with gallbladder pathology. Pain 114:239–249CrossRef

55.

Chapman CR, Syrjala KL (1990) Measurement of Pain. In: Bonica JJ (ed) The Management of Pain, 2nd edn. Lea & Febiger, Philadelphia, pp 580–594

56.

Fischer AA (1998) Muscle pain syndromes and fibromyalgia. Pressure algometry for quantification of diagnosis and treatment outcome. J Musculoske Pain 1:6–152

57.

Giamberardino MA, Costantini R (2017) Challenging chronic migraine: targeting the CGRP receptor. Lancet Neurol 16(6):410–411CrossRef

Title: Effects of topical vs injection treatment of cervical myofascial trigger points on headache symptoms in migraine patients: a retrospective analysis
Authors: Giannapia Affaitati
Raffaele Costantini
Claudio Tana
Domenico Lapenna
Cosima Schiavone
Francesco Cipollone
Maria Adele Giamberardino
Publication date: 01-12-2018
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2018
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-018-0934-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Effects of topical vs injection treatment of cervical myofascial trigger points on headache symptoms in migraine patients: a retrospective analysis

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial

Vascular wall imaging in reversible cerebral vasoconstriction syndrome – a 3-T contrast-enhanced MRI study

Myofascial trigger points in migraine and tension-type headache

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study

Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry

Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment